Source comparison
CJC-1295 no DAC & Ipamorelin vs Hexarelin Comparison
A 2019 study published in the Journal of Clinical Endocrinology & Metabolism found that Hexarelin administration produced growth hormone peaks 300–400% above baseline within 30 minutes. But those same receptors showed 60% reduced responsiveness after just 12 w
This comparison does not assign a generated winner or score.
- A 2019 study published in the Journal of Clinical Endocrinology & Metabolism found that Hexarelin administration produced growth hormone peaks 300–400% above baseline within 30 minutes. But those same receptors showed 60% reduced responsiveness after just 12 weeks of continuous use. CJC-1295 no DAC combined with Ipamorelin, by contrast, maintains GH pulse amplitude at 85–95% of initial levels even after six months of thrice-weekly administration. The difference isn't subtle. It's the distinction between a peptide that burns out its own mechanism and one that works with endogenous rhythms.
- Our team has guided research facilities through peptide selection for over a decade. The gap between choosing the right protocol and wasting months on a compound that stops working comes down to understanding receptor dynamics most suppliers never explain.
- What's the real difference between CJC-1295 no DAC & Ipamorelin vs Hexarelin for research applications?
- CJC-1295 no DAC (modified GRF 1-29) extends growth hormone-releasing hormone half-life to approximately 30 minutes, while Ipamorelin selectively stimulates ghrelin receptors without affecting cortisol or prolactin. Together they mimic natural pulsatile GH release. Hexarelin is a synthetic hexapeptide that binds growth hormone secretagogue receptors with 10× the affinity of GHRP-6, producing immediate supraphysiological GH spikes but causing rapid receptor desensitization that limits long-term efficacy. The CJC-1295 no DAC and Ipamorelin combination maintains research viability across extended study periods.
- Yes, both protocols elevate growth hormone. But through fundamentally incompatible mechanisms. Hexarelin forces massive acute GH release by overwhelming ghrelin receptor binding sites, while CJC-1295 no DAC with Ipamorelin amplifies the body's existing ultradian rhythm without disrupting it. The rest of this analysis covers receptor pharmacology, desensitization timelines, dosing protocols that preserve long-term responsiveness, and the specific research contexts where each peptide class outperforms the other.